Prostate cancer solution receives €2.1m backing from EIC

Quantib, an AI solutions provider for radiology, has been selected by the European Innovation Council (EIC) Accelerator fund for a €2.1 million grant, bringing total funding to over €12 million to date.

The selection was based on the potential that the company’s prostate cancer solution has to improve diagnosis, reduce costs, and improve patient outcomes.

Prostate cancer represents one in four of all cancer cases, yet accuracy, speed, invasiveness, and cost remain obstacles in diagnosis and eventual treatment. The EIC Accelerator grant will support Quantib to further develop its prostate solution which addresses these challenges, and to scale the solution to assist medical centres in the EU, US, and eventually, worldwide.

Arthuer Post Uiterweer, CEO of Quantib, said: “Quantib’s selection for a €2.1 million this Horizon 2020 grant is a major vote of confidence in the potential we have to further develop and scale a first of its kind AI solution for radiologists. We are already trusted by some of the world’s leading medical centres for solutions addressing key pathologies, but with this new funding, we will not only be able to develop another effective solution, we will also be well en route to becoming the market leader in addressing a major form of cancer.”

Quantib was previously funded by Holland Capital, a Netherlands’ tech investor, Innovation Quarter, the regional economic development agency for South Holland, and a series of EU and national grants and credits.